100% of our markets are now operating the new commercial model.
Our mission is to improve the quality of human life by enabling people to do more, feel better, live longer. Discover more about us below...
We invested £3.6 billion in 2016 in our search to develop new medicines, vaccines and consumer products.
We expect important data on between 20 and 30 assets in areas including HIV, respiratory, immuno-inflamation and oncology.
We have a network of 87 manufacturing sites, and large R&D centres in the UK, US and Belgium.
We have been the first in the Access to Medicines Index since its launch in 2008.
More than 16,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products.
In 2016, we distributed more than 883 million doses of vaccines around the world.
We employ around 99,300 people in over 150 countries, with more than a third of these in emerging markets.